Is Celgene (CELG) Outperforming Other Medical Stocks This Year?
Investors focused on the Medical space have likely heard of Celgene (CELG), but is the stock performing well in comparison to the rest of its sector peers? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Celgene is a member of our Medical group, which includes 887 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CELG is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CELG's full-year earnings has moved 7.43% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, CELG has moved about 68.03% on a year-to-date basis. Meanwhile, stocks in the Medical group have gained about 2.65% on average. As we can see, Celgene is performing better than its sector in the calendar year.
Looking more specifically, CELG belongs to the Medical - Biomedical and Genetics industry, a group that includes 376 individual stocks and currently sits at #57 in the Zacks Industry Rank. Stocks in this group have gained about 1.55% so far this year, so CELG is performing better this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on CELG as it attempts to continue its solid performance.
Click to get this free report
Celgene Corporation (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.